相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature
Medhavi Gupta et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling
Nicholas J. Cope et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K. S. Salama et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience
Cinthya Y. Lowder et al.
SURGICAL ONCOLOGY-OXFORD (2020)
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers
Aatur D. Singhi et al.
GASTROENTEROLOGY (2019)
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeting Alterations in the RAF-MEK Pathway
Rona Yaeger et al.
CANCER DISCOVERY (2019)
LBA-006BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer
S Kopetz et al.
ANNALS OF ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features
Jiro Watari et al.
SCIENTIFIC REPORTS (2019)
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer
Rona Yaeger et al.
CLINICAL CANCER RESEARCH (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
Alicia Latham et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Identification of targetable BRAFΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma
Kazimierz O. Wrzeszczynski et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
Zishuo I. Hu et al.
CLINICAL CANCER RESEARCH (2018)
Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative
Michael J. Pishvaian et al.
CLINICAL CANCER RESEARCH (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre et al.
CANCER DISCOVERY (2018)
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Christoph Heining et al.
CANCER DISCOVERY (2018)
Molecular Profiling of Pancreatic Cancer Patients-Response
Michael J. Pishvaian et al.
CLINICAL CANCER RESEARCH (2018)
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Zhan Yao et al.
NATURE (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Jeffrey S. Ross et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A. Foster et al.
CANCER CELL (2016)
Efficacy of of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations
Yen-Fu Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen et al.
CANCER DISCOVERY (2016)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma
Stephanie Trudel et al.
BMC CANCER (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer
James M. Lindberg et al.
NEOPLASIA (2014)
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
Stephanie Cardarella et al.
CLINICAL CANCER RESEARCH (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Identification of a Novel Complex BRAF Mutation Associated With Major Clinical Response to Vemurafenib in a Patient With Metastatic Melanoma
Benoit Busser et al.
JAMA DERMATOLOGY (2013)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
Hazem El-Osta et al.
PLOS ONE (2011)
Ras oncogenes: split personalities
Antoine E. Karnoub et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
BRAF and K-ras gene mutations in human pancreatic cancers
N Ishimura et al.
CANCER LETTERS (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
